BioCryst Pharmaceuticals Earnings: Here’s Why the Stock is Rising Now
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 6.38%.
BioCryst Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.09 in the quarter versus EPS of $-0.13 in the year-earlier quarter.
Revenue: Decreased 70.95% to $3.55 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: BioCryst Pharmaceuticals, Inc. reported adjusted EPS loss of $0.09 per share. By that measure, the company beat the mean analyst estimate of $-0.15. It beat the average revenue estimate of $1.31 million.
Quoting Management: “We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for regulatory approval in the U.S.,” said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst. “In addition, our Phase 1 clinical trial of BCX4161 in healthy subjects is progressing. We expect to complete this clinical trial and report results this summer. If this trial is successful, we plan to initiate a Phase 2 program in hereditary angioedema patients this year.”
Key Stats (on next page)…